(2-Pack) TIRZEPATIDE – 10mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
New England Journal of Medicine
72-week landmark trial of 2,539 patients showed tirzepatide achieved body weight reductions of 15.0–20.9% versus 3.1% placebo — establishing dual GIP/GLP-1 agonism superiority.
Tirzepatide Versus Semaglutide Once Weekly in Patients With Type 2 Diabetes (SURPASS-2)
New England Journal of Medicine
Head-to-head trial of 1,879 patients showed tirzepatide achieved superior HbA1c reduction and greater weight loss (5.5–7.3 kg) than semaglutide 1 mg.
Tirzepatide After Intensive Lifestyle Intervention in Adults With Overweight or Obesity (SURMOUNT-3)
Nature Medicine
72-week trial showed tirzepatide achieved additional 18.4% weight loss beyond intensive lifestyle intervention, with 95% reaching ≥5% total weight loss.
Efficacy and Safety of Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1)
The Lancet
40-week monotherapy trial showed tirzepatide produced superior HbA1c reduction of 1.9–2.5% and weight loss of 7.0–9.5 kg, with 92% achieving HbA1c <7%.
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
New England Journal of Medicine
Head-to-head comparison showed tirzepatide 15 mg reduced HbA1c by 2.46% vs semaglutide 1 mg 1.86%, with body weight reductions of 12.4 kg vs 6.2 kg at 40 weeks in 1,879 T2D patients.
Tirzepatide Once Weekly for the Treatment of Obesity in People Without Diabetes (SURMOUNT-1)
New England Journal of Medicine
In 2,539 adults with BMI ≥30, tirzepatide 15 mg produced 22.5% mean body weight loss at 72 weeks — the largest weight reduction ever achieved with a pharmaceutical agent at the time.